07:00 , Oct 28, 2010 |  BC Innovations  |  Targets & Mechanisms

STEP against AD

Yale University researchers have made a case for blocking STEP, a brain-specific phosphatase involved in synaptic signaling and a key player in the early stages of Alzheimer's disease development.1 Knocking down the enzyme forestalled AD...
07:00 , Aug 28, 2008 |  BC Innovations  |  Targets & Mechanisms

Curbing Mitochondrial Appetite

Several companies have tried and failed to develop obesity drugs that agonize mitochondrial uncoupling proteins, which let adipose cells generate heat by burning excess fat. A new study now suggests that one member of this...
08:00 , Feb 4, 2008 |  BC Week In Review  |  Clinical News

SA4503: Phase II started

M's Science began a double-blind, international Phase II trial to compare SA4503 to placebo in 60 patients. The company, which granted rights for the product in certain indications to AGY Therapeutics Inc. (South San Francisco,...
07:00 , Oct 2, 2006 |  BC Week In Review  |  Company News

Cerimon management update

Cerimon Pharmaceuticals Inc., South San Francisco, Calif.   Business: Autoimmune, Neurology, Inflammation   Hired: Timothy McBride as SVP of business development, formerly president and CEO of AGY Therapeutics Inc.   ...
08:00 , Mar 21, 2005 |  BC Week In Review  |  Company News

AGY Therapeutics management update

AGY Therapeutics Inc., South San Francisco, Calif.   Business: Neurology   Hired: Larry Powe as VP of clinical development, formerly director of clinical research at Amgen Inc.   ...
07:00 , Jul 26, 2004 |  BC Week In Review  |  Company News

AGY Therapeutics, M's Science deal

M's granted AGY exclusive rights to develop and commercialize AGY-94806 (or SA4503), a small molecule sigma receptor agonist, for certain indications. M's has completed a Phase I trial of the compound and will retain rights...
07:00 , Jul 26, 2004 |  BioCentury  |  Product Development

Different strokes for AGY

AGY Therapeutics Inc.'s deal with M's Science Corp. gets AGY into the clinic, but in an indication where many others have broken their picks: stroke. AGY is taking a different tack, and plans to develop...
08:00 , Feb 16, 2004 |  BC Week In Review  |  Company News

AGY Therapeutics other research news

Researchers published in the Journal of Biological Chemistry that in culture, cathepsin B inhibition via a small molcule or RNA interference significantly decreased the toxic effect of beta amyloid on neurons. AGY Therapeutics Inc.,...
08:00 , Feb 9, 2004 |  BC Week In Review  |  Company News

AGY Therapeutics management update

AGY Therapeutics Inc., South San Francisco, Calif.   Business: Neurology   Hired: Timothy McBride as SVP of business development, formerly CBO at Acologix Inc.   ...
07:00 , Jul 7, 2003 |  BC Week In Review  |  Company News

AGY Therapeutics, Cengent deal

Cengent will provide X-ray crystallography services to AGY for structure-based lead optimization. Cengent will receive upfront payments and is eligible for milestones. AGY Therapeutics Inc., South San Francisco, Calif.   Cengent Therapeutics Inc., San Diego, Calif....